A review of iniparib in ovarian cancer

Bibliography

• Howlader N, Noone AM, Krapcho M, editors. SEER cancer statistics review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute; Bethesda, MD: 2012. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/; based on November 2011 SEER data submission, posted to the SEER web site, April 2012
   Google Scholar
• National Comprehensive Cancer Network. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal version I. 2013. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp - ovarian [Cited 11/10/2012]
   Google Scholar
• Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291(22):2705-12
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305(22):2295-303
   PubMed Web of Science ®Google Scholar
• Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2012;157(12):900-4
   PubMed Web of Science ®Google Scholar
• Bristow RE, Montz FJ, Lagasse LD, Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72(3):278-87
   PubMed Web of Science ®Google Scholar
• Curtin JP, Malik R, Venkatraman ES, Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64(1):9-12
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47(2):159-66
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115(6):1234-44
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200
   PubMed Web of Science ®Google Scholar
• Parmar MK, Ledermann JA, Colombo N, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361(9375):2099-106
   PubMed Web of Science ®Google Scholar
• Roland PY, Barnes MN, Niwas S, Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Gynecol Oncol 1998;68(2):178-82
   PubMed Web of Science ®Google Scholar
• Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998;16(4):1494-7
   PubMed Web of Science ®Google Scholar
• Salani R, Santillan A, Zahurak ML, Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 2007;109(4):685-91
   PubMed Web of Science ®Google Scholar
• Chi DS, McCaughty K, Diaz JP, Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006;106(9):1933-9
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay-Oezcelik G, Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008;26(19):3176-82
   PubMed Web of Science ®Google Scholar
• Lortholary A, Largillier R, Weber B, Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 2012;23(2):346-52
   PubMed Web of Science ®Google Scholar
• Garcia AA, O'Meara A, Bahador A, Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004;93(2):493-8
   PubMed Web of Science ®Google Scholar
• Dizon DS, Hensley ML, Poynor EA, Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002;20(5):1238-47
   PubMed Web of Science ®Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J, Osborne C, Pippen JE, Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364(3):205-14
   PubMed Web of Science ®Google Scholar
• Ossovskaya V, Koo IC, Kaldjian EP, Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010;1(8):812-21
   PubMedGoogle Scholar
• Chuang HC, Kapuriya N, Kulp SK, Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012;134(2):649-59
   PubMed Web of Science ®Google Scholar
• Bookman MA, Brady MF, McGuire WP, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27(9):1419-25
   PubMed Web of Science ®Google Scholar
• Hess LM, Rong N, Monahan PO, Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer 2010;116(22):5251-60
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Helpirt F, Weber B, AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl):abstract LBA 5002
   Google Scholar
• Dantzer F, de La Rubia G, Menissier-De Murcia J, Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000;39(25):7559-69
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123-34
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913-17
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917-21
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner NC, Lord CJ, Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66(16):8109-15
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245-51
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12(9):852-61
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-9
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376(9737):235-44
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012;18(2):510-23
   PubMed Web of Science ®Google Scholar
• Patel AG, De Lorenzo SB, Flatten KS, Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012;18(6):1655-62
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy JSL, Danso MA, Rugo HS, A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;28:81s
   Google Scholar
• Fogelman DR, Wolff RA, Kopetz S, Evidence for the efficacy of iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011;31(4):1417-20
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Secord AA, Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2012;126(3):424-7
   PubMed Web of Science ®Google Scholar
• Mendeleyev J, Kirsten E, Hakam A, Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995;50(5):705-14
   PubMed Web of Science ®Google Scholar
• Kun E, Mendeleyev J, Hakam A, Kirsten E. Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide. Mol Med Rep 2009;2(5):739-42
   Web of Science ®Google Scholar
• Bauer PI, Mendeleyeva J, Kirsten E, Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease. Biochem Pharmacol 2002;63(3):455-62
   PubMed Web of Science ®Google Scholar
• Mahany JJ, Lewis N, Heath EI, A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors. J Clin Oncol 2008;26(May 20 suppl):abstract 3579
   Google Scholar
• Kopetz S, Mita MM, Mok I, First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors. J Clin Oncol 2008;26(May 20 Suppl):abstract 3577
   Google Scholar
• Penson RT, Whalen C, Lasonde B, A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 2011;29(Suppl):abstract 5004
   Google Scholar
• Birrer MJ, P Konstantinopoulos P, Penson RT, A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 2011;29(Suppl):abstract 5005
   Google Scholar